Automate Your Wheel Strategy on ELEV
With Tiblio's Option Bot, you can configure your own wheel strategy including ELEV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELEV
- Rev/Share 0.0
- Book/Share 0.7898
- PB 0.3876
- Debt/Equity 0.0
- CurrentRatio 19.4037
- ROIC -0.6294
- MktCap 18128375.0
- FreeCF/Share -0.5289
- PFCF -0.5793
- PE -0.3774
- Debt/Assets 0.0
- DivYield 0
- ROE -0.7468
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ELEV | Stephens | Overweight | Equal Weight | $5 | $1 | March 24, 2025 |
| Downgrade | ELEV | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | March 21, 2025 |
| Downgrade | ELEV | Leerink Partners | Outperform | Market Perform | -- | $1 | March 21, 2025 |
| Downgrade | ELEV | Piper Sandler | Overweight | Neutral | -- | $0.7 | March 21, 2025 |
| Initiation | ELEV | William Blair | -- | Outperform | -- | -- | Jan. 3, 2025 |
News
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON , April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) …
Read More
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Negative
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
Read More
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
Published: March 20, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
Read More
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 -- -- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 -- -- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 -- BOSTON , March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused …
Read More
About Elevation Oncology, Inc. (ELEV)
- IPO Date 2021-06-25
- Website https://elevationoncology.com
- Industry Biotechnology
- CEO Mr. Joseph J. Ferra Jr.
- Employees 34